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ABSTRACT
mTOR signalling is commonly dysregulated in cancer. Concordantly, mTOR 
inhibitors have demonstrated efficacy in a subset of tumors and are in clinical trials 
as combination therapies. Although mTOR is associated with promoting cell survival 
after DNA damage, the exact mechanisms are not well understood. Moreover, since 
mTOR exists as two complexes, mTORC1 and mTORC2, the role of mTORC2 in cancer 
and in the DNA damage response is less well explored. Here, we report that mTOR 
protein levels and kinase activity are transiently increased by DNA damage in an 
ATM and ATR-dependent manner. We show that inactivation of mTOR with siRNA or 
pharmacological inhibition of mTORC1/2 kinase prevents etoposide-induced S and 
G2/M cell cycle arrest. Further results show that Chk1, a key regulator of the cell cycle 
arrest, is important for this since ablation of mTOR prevents DNA damage-induced 
Chk1 phosphorylation and decreases Chk1 protein production. Furthermore, mTORC2 
was essential and mTORC1 dispensable, for this role. Importantly, we show that 
mTORC1/2 inhibition sensitizes breast cancer cells to chemotherapy. Taken together, 
these results suggest that breast cancer cells may rely on mTORC2-Chk1 pathway for 
survival and provide evidence that mTOR kinase inhibitors may overcome resistance 
to DNA-damage based therapies in breast cancer.
INTRODUCTION
Mammalian target of rapamycin (mTOR) is a 
serine-threonine kinase of the phosphoinositide 3-kinase-
related kinase (PIKK) family which plays a central role 
in cell growth and it is commonly dysregulated in cancer 
[1-6]. Other members of this family include ATM, ATR 
and DNA-PKcs, which have well established roles in 
DNA damage response signalling. mTOR is the catalytic 
component of two functionally distinct complexes, 
mTORC1 and mTORC2. mTORC1 is composed of 
mTOR, Raptor, LST8/GβL, PRAS40 and DEPTOR and its 
activity is stimulated by growth factor signals to regulate 
protein synthesis through 4E-BP1/2 and the S6 kinases, 
S6K1 and S6K2 [1, 7]. By contrast, mTORC2, which 
comprises mTOR, Rictor, LST8/GβL, DEPTOR, SIN1 
and PRR5 [1], regulates cytoskeletal organization [8, 9] 
and has a role in phosphorylation of AGC family members 
including PKC, Akt and SGK to promote cell survival and 
cell cycle progression [10-12].
Apart from regulating cell growth signalling, 
mTOR also responds to numerous cell stresses including 
nutrient and energy availability, as well as genotoxic 
stress, in order to promote cell survival [1]. However, 
how mTOR detects DNA damage and signals this to the 
DNA repair, cell cycle and cell death machineries is still 
poorly understood. While there is evidence that DNA 
damage eventually leads to mTORC1 inhibition through 
p53-dependent mechanisms [13, 14], there are also an 
increasing number of reports demonstrating that mTORC1 
positively regulates p53, [15-18] and that both mTORC1 
and mTORC2 pathways are activated following DNA 
damage [16, 19-21]. Recently, two groups have identified 
that mTORC1 regulates the DNA damage response 
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through the upregulation of FANCD2 gene expression, a 
key protein involved in the repair of DNA double-strand 
breaks [22, 23]. 
In this study we investigated how mTOR signals 
to the cell machinery to promote cell survival following 
DNA damage. We found that both mTORC1 and 
mTORC2 activities are transiently increased following 
DNA damage. Inactivation of mTOR, with siRNA or an 
mTORC1/2 kinase inhibitor, prevented DNA damage 
induced S and G2/M cell cycle arrest as well as Chk1 
activation, demonstrating a requirement of mTOR for 
cell survival by establishing efficient cell cycle arrest. 
Furthermore, we show that ablation of mTORC2 prevents 
Chk1 activation and augments DNA damage-induced cell 
death, suggesting that breast cancer cells may rely on the 
mTORC2-Chk1 pathway for survival. 
RESULTS
mTOR regulation in response to etoposide-
induced DNA damage
To examine the regulation of mTOR in response 
to DNA damage, HEK293 cells were treated with 
etoposide, a topoisomerase II inhibitor which induces 
double strand DNA breaks. The level of total mTOR and 
phosphorylation at Ser2448 and Ser2481 were analysed 
by western blot at 4, 8 and 24 hrs following etoposide 
treatment (Figure 1A). We observed a transient increase 
in total mTOR and phosphorylation at Ser2448 and 
Ser2481 at 4 hrs after etoposide-induced DNA damage. 
Total mTOR and phosphorylation levels were eventually 
decreased at 24 hrs after DNA damage, in agreement with 
previous reports [13, 14]. We further explored the DNA 
Figure 1: (A) Etoposide-induced DNA damage transiently increases mTOR. HEK293 cells were treated with 100 µM of etoposide 
for 4, 8 and 24 hrs. Whole-cell lysates were assayed by western blot for mTOR and phosphorylated-mTOR (Ser2448 and Ser2481). Actin 
was used as loading control. (B) DNA damage-induced increase in mTOR activity is concentration dependent. HEK293 cells were treated 
with increasing concentrations of etoposide for 4 hrs. Whole-cell lysates were assayed by western blot for mTOR, phosphorylated mTOR 
(Ser2448), Akt and phosphorylated Akt (Ser473), p70S6K and phosphorylated p70S6K (Ser371). Actin was used as loading control. (C) 
DNA-damage induced increase in mTOR activity in breast cancer cells. MCF7 cells were treated with 50 and 100 µM etoposide for 4 
hrs. Whole-cell lysates were assayed by western blot for mTOR, phosphorylated mTOR (Ser2448), p70S6K and phosphorylated p70S6K 
(Ser371). Actin was used as loading control.
Oncotarget429www.impactjournals.com/oncotarget
damage-induced transient increase in mTOR and found a 
concentration dependent increase in mTOR activity at 4 
hrs. mTOR protein level and phosphorylation at Ser2448 
were induced by increasing concentrations of etoposide 
(Figure 1B). In addition, phosphorylation of p70S6K 
and Akt, downstream targets of mTORC1 and mTORC2 
respectively were also increased (Figure 1B). Similar 
results were observed for MCF7 breast cancer cells with 
a concentration-dependent increase of phosphorylated 
mTOR and p70S6K as well as total levels of mTOR 
(Figure 1C). Collectively these results demonstrate that 
mTOR protein and its kinase activity are increased in 
response to early DNA damage.
mTOR is induced by etoposide in an ATM and 
ATR-dependent, and p53-independent manner
Previous studies have demonstrated intricate 
signalling between the mTOR and p53 pathways in 
response to DNA damage [13, 14]. A number of reports 
have described p53-mediated down regulation of mTOR 
signalling [13]. In addition, it has also been shown 
that increased mTOR activity positively regulates p53 
accumulation and function [16, 17, 24, 25]. We were 
interested in the role of p53 in etoposide-induced increase 
of mTOR and therefore assessed isogenically matched 
p53+/+ and p53-/- HCT116 cells. Etoposide-induced 
accumulation of mTOR was observed in both p53+/+ and 
p53-/- cells indicating that mTOR upregulation following 
early DNA damage was not dependent on p53 (Figure 
2A). Next we assessed the role of key regulators of the 
DNA damage response, ATM and ATR, on etoposide-
induced increase in mTOR. An ATM-specific inhibitor 
was used to establish whether DNA damage-induced 
transient upregulation of mTOR was dependent on 
ATM. The transient increase in mTOR following 4 hrs 
of etoposide treatment was suppressed in the presence 
of the ATM inhibitor in both p53+/+ and p53-/- HCT116 
cells (Figure 2A). p53 is a well-studied target of ATM 
which was monitored by western blot to confirm that 
the ATM inhibitor was effective (Supplementary Figure 
1). These results are consistent with a previous report 
Figure 2: (A) Etoposide induced increase in mTOR is ATM-dependent and p53-independent. HCT116 p53+/+ cells and HCT116 
p53-/- cells were pre-treated in the absence or presence of 10 µM ATM inhibitor (ATMi) for 1 hr before incubation with 100 µM etoposide 
for 4 hrs. Whole-cell lysates were assayed by western blot for mTOR. Actin was used as a loading control. (B) Etoposide induced increase 
in mTOR is ATR-dependent. HEK293 cells were transiently transfected with AllStars siRNA control duplexes or ATR siRNA for 72 hrs. 
100 µM of etoposide was added at 4 hrs prior to the end of 72 hrs incubation period. Whole-cell lysates were assayed by western blot 
for ATR, mTOR and phosphorylated mTOR (Ser2481), Chk1 and phosphorylated Chk1 (Ser345). Actin was used as loading control. (C) 
mTOR accumulation induced by etoposide is stabilisation. HCT116 p53+/+ cells (left panels) and HCT116 p53-/- cells (right panels) were 
pre-treated in the absence or presence of 10 µM cycloheximide for 1 hr before incubation with either 10 µM of MG-132 or 100 µM of 
etoposide for a further 4 hrs. Whole-cell lysates were assayed by western blot for mTOR. Actin was used as a loading control. 
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demonstrating a requirement of ATM for the initial 
transient increase in protein synthesis induced by DNA 
damage that was mediated by mTORC1 [26]. In addition, 
we downregulated ATR using siRNA in HEK293 cells to 
determine whether etoposide induction of both mTOR 
protein and phosphorylation at Ser2481 were dependent 
on ATR (Figure 2B). To ensure that ATR siRNA had 
sufficiently suppressed ATR activity, phosphorylation 
of Chk1 (Ser345), a well-known substrate of ATR, was 
monitored by western blot (Figure 2B).Taken together, 
our results show that etoposide-induced increase in mTOR 
is independent of p53, but dependent on ATM and ATR 
activity. 
In order to explore the mechanism of etoposide-
induced increase in mTOR protein level, HCT116 p53+/+ 
and p53-/- cells were either treated with cycloheximide, 
an inhibitor of protein synthesis, or the proteasome 
inhibitor, MG-132 (Figure 2C). Incubation of cells with 
cycloheximide alone resulted in inhibition of mTOR 
protein suggesting a requirement for ongoing protein 
synthesis to maintain basal mTOR levels. However, 
the etoposide-mediated increase in mTOR protein 
accumulation was still observed in both p53+/+ and 
p53-/- HCT116 cells in the presence of cycloheximide, 
indicating that etoposide-mediated increase in mTOR 
was unlikely due to increased protein synthesis. We next 
investigated the effect of MG-132 on the level of mTOR 
in HCT116 cells. Treatment of cells with MG-132 for 4 
hrs led to an accumulation of mTOR protein similar to 
that observed for etoposide treatment (Figure 2C), either 
in the absence or presence of cycloheximide, further 
suggesting that etoposide-mediated upregulation of mTOR 
was not dependent on protein synthesis, but rather due to 
stabilization of mTOR.
mTOR is required for efficient DNA damage-
induced cell cycle arrest
The central role of the DNA damage response is to 
enhance cell survival. This is achieved by a coordinated 
response to DNA damage that delays cell cycle 
progression in order to maximize DNA repair. As mTOR 
is a key regulator of the cell cycle [27], we next assessed 
whether mTOR enhanced cell survival in response to DNA 
damage by promoting cell cycle arrest. DNA damage 
was induced in HEK293 cells with etoposide for 16 or 
24 hrs in the absence or presence of an ATP competitive 
inhibitor of mTOR, PP242, which inhibits both mTORC1 
and mTORC2 complexes [28], and the percentage of cells 
in different phases of the cell cycle was analysed by flow 
cytometry (Figure 3A and 3B). In the absence of PP242, 
efficient S and G2/M arrest was observed following 
etoposide treatment in HEK293 cells (Figure 3A and B). 
Importantly, a significant inhibition of cell cycle arrest 
was observed when mTOR activity was attenuated with 
PP242 (Figure 3A and B). Furthermore, siRNA-mediated 
downregulation of mTOR also led to a striking inhibition 
of both S and G2/M cell cycle arrest (Figure 3C and 3D). 
Taken together, these results show that mTOR is required 
for efficient DNA damage-induced S and G2/M cell cycle 
arrest. 
mTOR is required for DNA damage-induced 
Chk1 activation
Key regulators of the DNA damage-induced cell 
cycle arrest include Chk1, Chk2 and p53 proteins [29]. 
We therefore assessed whether mTOR is required to 
activate these proteins by observing the status of the DNA 
damage-induced phosphorylation and their total protein 
levels. Western blot analysis revealed that etoposide-
induced increase in phosphorylation and total protein 
level of Chk1, and p53 were reduced by pharmacological 
inhibition of mTOR kinase at 4 and 24 hrs. Although Chk2 
phosphorylation was unaffected at 4hrs, it was reduced at 
24 hrs (Figure 3E). To confirm that the effects we observed 
were specific to mTOR, we downregulated mTOR with 
siRNA and found that etoposide-induced phosphorylation 
of Chk1 and Chk2 were reduced as well as total Chk1 
level (Figure 3F). Overall, DNA damage-induced 
phosphorylation of the histone protein, H2AX, a key 
indicator of the amount of damaged DNA, did not appear 
to be affected by mTOR inhibition (Figure 3E and F). 
In conclusion, these results show that mTOR is required 
for efficient DNA damage-induced cell cycle arrest, and 
this is possibly mediated by regulation of key cell cycle 
proteins Chk1, Chk2 and p53. mTOR-dependent induction 
of p53 after DNA damage has previously been reported 
[16, 18, 24, 30] and as HEK293 cells used here are known 
to have non-functional p53 [31], we further assessed 
mTOR-dependent regulation of Chk1 and Chk2 after DNA 
damage. We also extended our studies to include breast 
cancer cells as mTOR is emerging as an important target 
for breast cancer treatment. Pharmacological inhibition 
of mTOR with PP242 inhibited early etoposide- and UV-
induced Chk1 phosphorylation in MCF7 cells, but not 
Chk2 phosphorylation (Figure 4A and 4B). In addition, 
siRNA-mediated downregulation of mTOR reduced 
total Chk1 level and phosphorylation, but not Chk2 
phosphorylation, when a lower concentration of etoposide 
was used (Supplementary Figure 2). Therefore we decided 
to focus primarily on how mTOR is required for Chk1 
regulation following early DNA damage. 
It was evident from Figure 3 (E and F) that mTOR 
inhibition with PP242 or siRNA caused a reduction in 
total Chk1 protein and its phosphorylation, following 
etoposide-induced DNA damage in HEK293 cells. 
To dissect the mechanism of how mTOR regulates 
Chk1 we observed Chk1 under various conditions and 
in different cell lines. First we assessed the status of 
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phosphorylation residues and total Chk1 level in HEK293 
cells following etoposide-induced DNA damage from 15 
minutes to 4hrs (Figure 4C). Following DNA damage, 
Chk1 is phosphorylated at Ser345 and Ser317 leading to 
autophosphorylation at Ser296 and Chk1 activation [32, 
33]. As expected, etoposide-induced phosphorylation of 
these three residues of Chk1 from 15 minutes to 4 hrs 
(Figure 4C), all of which were inhibited in the presence 
of PP242 treatment (Figure 4C). In addition, as previously 
observed in HEK293 cells, PP242 also suppressed total 
Chk1 level following etoposide-induced DNA damage 
(Figure 4C). However, when ultraviolet (UV) irradiation 
was used as the DNA damaging agent, all three UV-
induced Chk1 phosphorylations were reduced by PP242 
Figure 3: (A) mTOR is required for efficient DNA damage-induced S and G2/M cell cycle arrest. HEK293 cells were incubated 
in the absence or presence of 400 nM of PP242 for 1 hr before addition of 100 µM of etoposide for 16 and 24 hrs. Cells were fixed in 
ethanol and DNA was stained with propidium iodide and DNA content was assayed by flow cytometry (B) The percentage of cells in each 
cell cycle phase (G2/M, S, G1 and Sub G1) is shown. Bars represent mean ± SEM of three separate experiments. Statistical analysis was 
performed using two-way ANOVA with Bonferroni post-test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (C) HEK293 cells were 
transiently transfected with AllStars control duplex or mTOR siRNA for 72 hrs. 100 µM of etoposide was added 16 and 48 hrs prior to the 
end of 72 hrs incubation period. Cells were fixed in ethanol and DNA was stained with propidium iodide and DNA content was determined 
by flow cytometry. (D) The percentage of cells in each cell cycle phase (G2/M, S, G1 and Sub G1) is shown. Bars represent mean ± SEM 
of three separate experiments. Statistical analysis was performed using two-way ANOVA with Bonferroni post-test. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001. (E) HEK293 cells were incubated in the absence or presence of 400 nM of PP242 for 1hr before addition 
of 100 µM of etoposide for 4 and 24 hrs. Whole-cell lysates were assayed by western blot for mTOR, Chk1 and phosphorylated Chk1 
(Ser296), Chk2 and phosphorylated Chk2 (Thr68), p53 and phosphorylated p53 (Ser15), and phosphorylated histone H2AX (Ser139). 
Actin was used as a loading control. Chk1 protein and phosphorylated Chk1 (Ser296) expression levels were determined by densitometry 
and presented on a column graph. (F) HEK293 cells were transiently transfected with AllStars siRNA control duplexes or mTOR siRNA 
for 72 hrs. 100 µM of etoposide was added at 4 and 48 hrs prior to the end of 72 hrs incubation period. Whole-cell lysates were assayed by 
western blot for mTOR, Chk1 and phosphorylated Chk1 (Ser296), Chk2 and phosphorylated Chk2 (Thr68), and phosphorylated histone 
H2AX (Ser139). Actin was used as loading control. Chk1 protein and phosphorylated Chk1 (Ser296) expression levels were determined by 
densitometry and presented on a column graph.
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in HEK293 cells without affecting total Chk1 protein 
level (Figure 4D). PP242 also prevented UV-induced 
Chk1 phosphorylation (Ser345) in MCF7 cells without 
affecting the total Chk1 level (Figure 4B). Furthermore, 
in other breast cancer cell lines (HBL100, MDA-
MB-231 and HCC1937), PP242 (Figure 4E) and mTOR 
siRNA treatment in HBL100 cells (Figure 4F) inhibited 
all three Chk1 phosphorylations induced by etoposide. 
Interestingly, similar to HEK293 cells, mTOR inhibition 
caused a reduction in total Chk1 level following etoposide 
treatment in HCC1937 cells but not in HBL100 and 
MDA-MB-231 cell lines (Figure 4E and F). Collectively 
Figure 4: (A) Pharmacological inhibition of mTOR suppresses etoposide-induced Chk1 activation not Chk2. MCF7 cells 
were treated in the absence or presence of 400 nM PP242 for 1 hr before addition of 50 µM and 100 µM etoposide for 4 hrs. Whole-cell 
lysates were analyzed by western blot for phosphorylated mTOR (Ser2448), Chk1 (Ser345), and Chk2 (Thr68) and total protein levels of 
Chk1 and Chk2. Actin was used as a loading control. (B) Pharmacological inhibition of mTOR suppresses UV-induced Chk1 activation 
not Chk2. MCF7 cells were exposed to 10 and 20 joules of UV and left to recover in the presence of 400nM of PP242 for 4hrs. Whole-
cell lysates were analyzed by western blot for phosphorylated mTOR (Ser2448), Chk1 and phosphorylated Chk1 (Ser345), Chk2 and 
phosphorylated Chk2 (Thr68). Actin was used as a loading control. (C) PP242 prevents etoposide-induced Chk1 phosphorylations and 
Chk1 protein level. HEK293 cells were incubated with 50 µM of etoposide in the absence and presence of 200 nM of PP242 for the time 
points indicated. Whole-cell lysates were assayed by western blot for Chk1 and phosphorylated Chk1 (Ser345, Ser296 and Ser317), Akt 
and phosphorylated Akt (Ser473). Actin was used as loading control. (D) PP242 prevents UV-induced Chk1 phosphorylations but not Chk1 
protein level. HEK293 cells were exposed to 10 and 20 joules of UV and left to recover in the absence and presence of 400nM of PP242 
for 2hrs. Whole-cell lysates were assayed by western blot for phosphorylated mTOR (Ser2448), Chk1 and phosphorylated Chk1 (Ser345, 
Ser296 and Ser317). Actin was used as loading control. (E) PP242 prevents etoposide-induced Chk1 phosphorylations in breast cancer cell 
lines. HBL100, MDA-MB-231 and HCC1937 cells were treated in the absence or presence of 400 nM PP242 for 1 hr before addition of 50 
µM etoposide for 4 hrs. Whole-cell lysates were analysed by western blot for Chk1 and phosphorylated Chk1 (Ser345, Ser317 and Ser296). 
Actin was used as a loading control. (F) Ablation of mTOR with siRNA inhibits etoposide-induced Chk1 phosphorylations but not Chk1 
protein in HBL100 cells. HBL100 cells were transiently transfected with AllStars control siRNA duplexes or siRNA to mTOR for a total of 
72 hr. 50 µM of etoposide was added 4 hr before the end of the 72 hrs period. Whole-cell lysates were analysed by western blot for mTOR, 
Chk1 and phosphorylated Chk1 (Ser345, Ser317 and Ser296), Akt and phosphorylated Akt (Ser473). Actin was used as a loading control.
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these results show that in all cell lines used in this study 
and by two different types of DNA damage induction, and 
two different types of mTOR inhibition, all three DNA 
damage-induced phosphoryations of Chk1 require mTOR 
activity. In addition, the total level of Chk1 also requires 
mTOR but in a cell-specific manner and depending on 
the type of DNA damage induction. Taken together these 
results demonstrate that mTOR is required for DNA 
damage induced Chk1 activity. 
mTOR regulates Chk1 production following 
etoposide-induced DNA damage
Since mTOR inhibition in HEK293 cells 
significantly reduced the total Chk1 level following 
etoposide treatment (Figure 3), we explored how mTOR 
regulates Chk1 protein in these cells. The reduction in 
Chk1 level caused by mTOR inhibition could be due to 
faster degradation of Chk1 or inhibition of its production 
at transcriptional or translational level. Therefore, we 
first observed the half-life of Chk1 using cycloheximide. 
In agreement with past reports [34-36] the turnover of 
Figure 5: (A) mTOR inhibition does not decrease Chk1 half-life following DNA damage. HEK293 and HCC116 (p53+/+) cells 
were treated with 100µM etoposide or 400nM PP242+100µM etoposide for 4hrs, prior to this end 10 µM cycloheximide (CHX) was added 
for 1, 2 and 4hrs. As control cycloheximide alone was added for 1, 2 and 4hrs. Whole-cell lysates were analysed by western blot for Chk1. 
Actin was used as a loading control. Chk1 protein was determined by densitometry and normalised to 0 hr control, which is set as 1. (B) 
Pharmacological inhibition of mTOR does not affect Chk1 mRNA level after DNA damage. HEK293 cells were treated in the absence or 
presence of 400 nM PP242 for 1 hr before addition of 100 µM etoposide for 4 hrs. mRNA expression of Chk1 was assessed by real-time 
PCR relative to GAPDH. Mean±S.E. of duplicate values of one representive experiment shown. (C) mTOR inhibition does not cause 
further decrease in Chk1 protein in the presence of translation inhibitor after DNA damage. HEK293 cells were pre-treated with 10µM of 
cycloheximide, or 400nM PP242, or together for 1hr followed by 100µM etoposide for further 4 hrs. As controls cells were treated with 
100µM etoposide for 4hrs, or 10µM cycloheximide, 400nM PP242 or together for 5 hrs. Whole-cell lysates were assayed by western blot 
for Chk1 and phosphorylated Chk1 (Ser345, Ser317 and Ser296). Actin was used as loading control. 
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Chk1 protein was significantly increased by etoposide-
induced DNA damage in both HEK293 and HCT116 cells 
(Figure 5A). mTOR inhibition with PP242 following DNA 
damage did not further increase Chk1 turnover, therefore 
it is unlikely that the decrease in Chk1 caused by mTOR 
inhibition is due to an increase in Chk1 degradation. 
Unexpectedly, PP242 in fact reduced Chk1 turnover 
following DNA damage. Zhang [34] demonstrated 
that DNA damage induced phosphorylation of Chk1 at 
Ser345 targets it for ubiquitin-mediated proteasomal 
degradation. Since we observed that PP242 inhibited 
Chk1 phosphorylation at Ser345, this could account for 
why Chk1 degradation is prevented. Nevertheless, total 
Chk1 is still reduced by mTOR inhibition following 
etoposide-induced DNA damage. Therefore, these results 
indicate that mTOR inhibition causes Chk1 reduction by 
inhibiting its production. Next we measured Chk1 mRNA 
levels using RT-PCR and found that they were not changed 
by etoposide-induced DNA damage, nor by mTOR 
inhibition with PP242 (Figure 5B). Thereby showing 
that mTOR regulation of Chk1 protein production is not 
mediated through transcription. However, in the presence 
of cycloheximide Chk1 level is efficiently suppressed 
before and after DNA damage, more importantly PP242 
did not cause a further reduction in Chk1 (Figure 5C) 
implying that Chk1 reduction caused by mTOR inhibition 
is mediated by preventing its synthesis at translation 
level. These results collectively suggest that following 
etoposide-induced DNA damage mTOR regulates Chk1 
production through protein synthesis. Figure 5C further 
supports our concept that mTOR is required for Chk1 
phosphorylation and activation independently from 
its regulation of total Chk1 protein. In the presence of 
cycloheximide, total Chk1 is suppressed but not further 
reduced by PP242. In the presence of cycloheximide, 
all three etoposide-induced Chk1 phosphorylations are 
reduced but PP242 causes additional reduction. 
mTORC2 complex is required for etoposide-
induced activation of Chk1
In mammalian cells, mTOR forms two functionally 
distinct complexes, mTORC1 and mTORC2, which 
contain shared and distinct partners. While mTORC1 
exclusively contains a scaffolding protein, Raptor, 
required for its function [37] mTORC2 complex contains 
Rictor, needed for its assembly [10]. PP242 inhibits 
both mTORC1 and mTORC2 complexes, therefore in 
order to dissect out the contribution of mTORC1 and/
or mTORC2 to DNA damage mediated Chk1 regulation 
we used rapamycin, which predominantly inhibits 
mTORC1, as well as specific downregulation of Raptor 
and Rictor with siRNA. Rapamycin had no effect on early 
etoposide-induced Chk1 phosphorylation and protein 
level as compared with PP242 (Figure 6A), suggesting 
that mTORC1 activity was dispensable for DNA damage 
mediated regulation of Chk1. Instead these data suggested 
a requirement of mTORC2 for etoposide-induced 
Chk1 activation as siRNA against Raptor (selective 
downregulation of mTORC1) did not affect Chk1, 
whereas siRNA against Rictor (selective downregulation 
of mTORC2) did prevent etoposide-induced Chk1 
phosphorylation and total Chk1 protein level (Figure 6B). 
Figure 6: (A) Etoposide-induced Chk1 activation is independent of mTORC1. HEK293 cells were treated in the absence or 
presence of 400 nM of PP242 or 100 nM of rapamycin for 1 hr before addition of 100 µM of etoposide for 4 hrs. Whole-cell lysates were 
assayed by western blot for phosphorylated mTOR (Ser2448), Chk1 and phosphorylated Chk1 (Ser345). Actin was used as a loading 
control. (B) Etoposide-induced Chk1 activation is dependent on mTORC2. HEK293 cells were transiently transfected with AllStars control 
duplexes or siRNA against mTOR, Raptor or Rictor for 72 hrs. 50 µM of etoposide was added 4 hrs prior to the end of 72 hrs incubation 
period. Whole-cell lysates were assayed by western blot for protein levels of mTOR, Raptor, Rictor, Chk1 and phosphorylated Chk1 
(Ser345). Actin was used as loading control. 
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These results are in line with recent work suggesting an 
increasing role of mTORC2 in cell cycle progression [38]. 
Taken together, these results show that early etoposide-
induced increase in Chk1 phosphorylation and total Chk1 
protein was dependent on mTORC2.
mTORC1/2 inhibition sensitizes breast cancer 
cells to chemotherapy
mTOR inhibitors can either sensitize cells to 
chemotherapy or attenuate the ability of chemotherapeutics 
to induce apoptosis through multiple mechanisms which 
are not yet fully elucidated but seem to depend, at least 
in part, on the genetic context of cells. For example, the 
rapalog everolimus, sensitized lung carcinoma cells to 
cisplatin treatment [15], whereas in colon cancer and 
renal carcinoma cell lines, pharmacological inhibition 
of mTOR kinase prevented chemotherapy-induced cell 
death [24, 39]. In HEK293 cells, the inhibition of mTOR 
activity using both PP242 and siRNA led to an increase 
in etoposide-induced cell death, as evidenced from 
the increase in the sub G1 population (Figure 3B and 
3D). In breast cancer, the mTOR signalling pathway is 
commonly dysregulated and is implicated in resistance 
to current treatment [40, 41]. We analysed a panel of 
Figure 7: (A) Pharmacological inhibition of mTORC1/2 sensitizes breast cancer cells to chemotherapy-mediated cell death. 
HBL100, MDA-MB-231, MCF7 and HCC1937 breast cells were seeded at 1.5x104 cells/ cm2 in 96-well plates and incubated in the 
absence or presence of 400 nM of PP242 for 1 hr, before addition of etoposide at the concentrations indicated for 24 hrs. Cell viability was 
assessed by MTT assay. Bars represent the mean ± SEM of three separate experiments. Statistical analysis was performed using two-way 
ANOVA with Bonferroni post-test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (B) Pharmacological inhibition of mTOR suppresses 
etoposide-induced Chk1 activation in breast cancer cells. HBL100, MDA-MB-231, MCF7 and HCC1937 breast cells were incubated in 
the absence or presence of 400 nM of PP242 for 1 hr, before addition of etoposide at the concentrations indicated for 24 hrs. Whole-cell 
lysates were assayed by western blot for Chk1 and phosphorylated Chk1 (Ser345), Akt and phosphorylated Akt (Ser473). Actin was used 
as loading control. (C) Proposed model for mTORC2 regulation of the DNA damage response. A transient increase in mTORC2 activity 
after DNA damage by ATM/ATR contributes to the activation of Chk1 and efficient S and G2M cell cycle arrest which allows more time 
for DNA repair and cell survival. Consequently, when mTORC2 is inhibited Chk1 activation and cell cycle arrest is prevented and the time 
for repair is removed, which allows DNA damage to induce cell death more effectively.
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breast cancer cell lines to assess cell viability following 
etoposide-induced DNA damage (Figure 7A). One 
cell line, HBL100, an immortalized epithelial cell line, 
displayed high sensitivity to etoposide as compared with 
three other breast cancer cell lines, MDA-MB-231, MCF7 
and HCC1937, which demonstrated varying degrees of 
resistance to etoposide (Figure 7A). Importantly, this 
resistance was overcome by the inhibition of mTOR 
activity with PP242, which significantly decreased breast 
cancer cell viability following DNA damage (Figure 7A). 
Consistent with our previous results, western blot analysis 
revealed that etoposide-induced Chk1 phosphorylation 
was strikingly inhibited by PP242 in all breast cell lines 
tested (Figure 7B). Interestingly the total Chk1 protein 
level was also reduced by PP242 following DNA damage 
in these cells with the exception of HBL100 (Figure 7B). 
The mTORC2-specific phosphorylation of Akt at Ser473 
was also monitored by western blot to confirm that 
mTORC2 activity was sufficiently inhibited by PP242 in 
these cell lines. Collectively, these results demonstrate 
that inhibition of mTOR activity significantly potentiates 
etoposide-mediated cell death in breast cancer, suggesting 
that breast cancer cells may rely on the mTORC2-Chk1 
pathway for survival. In line with this, recent work has 
demonstrated that cisplatin-induced apoptosis was 
significantly increased by loss of Rictor but not Raptor in 
breast and ovarian cancer cells [40, 42].
DISCUSSION
Since its discovery as the target of rapamycin, 
mTOR has been identified as a crucial mediator of protein 
synthesis, cell growth, and metabolism. mTORC1 is 
also important for relaying signals to the cell machinery 
in response to DNA damage. A number of studies have 
demonstrated that mTORC1 is downregulated in response 
to DNA damage in a p53 dependent manner [13, 14]. 
However, others have reported an increase in mTOR 
kinase activity in response to DNA damage [16, 19-21]. 
The mechanism by which mTOR promotes cell survival 
under conditions of DNA damage is poorly understood. 
Here, we found an increase in both mTORC1 and 
mTORC2 activity induced by early DNA damage. In 
addition, mTOR protein levels were transiently increased 
by etoposide treatment in several cell lines. This observed 
increase was not due to increased protein synthesis, but 
likely due to a transient stabilization of mTOR that was 
dependent on ATM and ATR and independent of p53. As 
mTOR is a key regulator of cell cycle progression from G1 
to S phase [27], we investigated whether mTOR promotes 
cell survival following DNA damage by regulating cell 
cycle arrest, which would consequently allow more time 
for DNA repair. Indeed, our results show that inhibition 
of mTOR by both siRNA and a specific inhibitor caused 
a striking inhibition of etoposide-induced S and G2/M 
cell cycle arrest. Further analysis revealed that the 
activation of a key cell cycle arrest regulator Chk1 was 
dependent on mTOR, as mTOR inhibition prevented 
etoposide-induced increase of Chk1 phosphorylation 
and total protein level. mTOR inhibition with siRNA, 
against mTOR or Rictor, or with PP242 consistently 
caused a reduction in Chk1 phosphorylation in all cell 
lines used in this study and by two different types of DNA 
damage, thereby demonstrating a requirement for mTOR 
in Chk1 activation following DNA damage. In addition, 
mTOR inhibition caused a reduction in Chk1 protein 
level under certain conditions, particularly in HEK293 
cells after etoposide-induced DNA damage. Since Chk1 
is degraded faster after DNA damage and we found no 
change in mRNA expression, mTOR most likely regulates 
Chk1 at translational level. The mechanism of how 
mTOR regulates Chk1 phosphorylation remains to be 
investigated. ATR is known to directly phosphorylate and 
activate Chk1, however we found ATR to be upstream of 
mTOR. It will be interesting in future studies to identify 
if mTOR or one of its downstream targets are responsible 
for Chk1 phosphorylation, or whether mTOR is involved 
in the regulation of Chk1 phosphatases [43].
In this study we show that mTORC2 and not 
mTORC1 regulates Chk1 following DNA damage. A 
previous report has demonstrated that mTORC2 regulates 
cell survival following DNA damage as glioblastoma 
cells with elevated mTORC2 activity were resistant 
to chemotherapy which was overcome by mTORC2 
inhibition [44]. In addition, TORC2 mediated actin 
filament regulation to promote cell survival following low 
DNA damage in yeast [45]. Our work is the first to link 
mTORC2 to Chk1 regulation in DNA damage response 
signalling to promote cell survival. 
We also observed an effect of mTOR inhibition 
on the DNA damage-dependent phosphorylation of 
Chk2 (Figure 3E and 3F). However, this effect was only 
observed following late DNA damage (24 h after etoposide 
treatment) which suggests that mTOR-dependent 
regulation of the S and G2/M cell cycle arrest is mainly 
dependent on Chk1 and not Chk2. However, this does not 
exclude a role for mTOR-dependent regulation of Chk2 in 
the DNA damage response as a recent report shows that in 
response to DNA damage, mTORC1 through FANCD2 is 
required for ATM-Chk2 activation in rhabdomyosarcoma 
cells [22].
mTOR signalling is commonly activated in cancer 
which has led to the generation of a number of mTORC1 
inhibitors (rapalogs) that have demonstrated clinical 
efficacy in a subset of cancers including relapsed renal cell 
carcinoma [46] and postmenopausal hormone-receptor-
positive breast cancer [47]. It has become increasingly 
clear that mTORC1 and mTORC2 exert distinct cellular 
functions, and that combined inhibition of both complexes 
may fully exploit the anti-cancer potential of targeting 
mTOR. Indeed, in a panel of breast cancer cell lines, cell 
survival was significantly decreased when etoposide was 
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combined with pharmacological inhibition of mTORC1/2, 
demonstrating that mTORC1/2 inhibitors are able to 
sensitize breast cancer cells to chemotherapy, consistent 
with a previous study [40]. An important question for the 
clinical development of mTOR inhibitors is why ablation 
of mTOR kinase sensitizes some cancer cells to DNA 
damage-induced cell death, but has the opposite effect in 
other cell types. For example, we and others have shown 
that mTOR inhibition attenuates chemotherapy-mediated 
cell death in colon and renal cell carcinoma cell lines 
[24, 39], and in certain genetic contexts, such as loss of 
TSC1/2 [18] or REDD1 [17]. The molecular mechanisms 
underlying these differential effects of mTOR inhibition 
in different cellular contexts is poorly understood, but is 
likely to depend on multiple pathways. One possibility is 
that the p53 status of cells is crucial, since loss of TSC1/2 
or REDD1 leads to hyperactive mTOR and increased p53 
translation [17, 18]. Consequently, in cells that undergo 
DNA damage-induced p53-dependent cell death, mTOR 
ablation could prevent p53-mediated cell death. However, 
in cells that depend on alternative apoptotic pathways 
and/or rely on mTORC2-Chk1 for cell cycle arrest, then 
by preventing appropriate cell cycle checkpoints, mTOR 
inhibition can augment cell death. While further studies 
are required to delineate the underlying mechanisms, 
collectively, these data highlight the need for careful 
evaluation of the genetic context of cells in order to fully 
exploit the use of targeted mTOR therapeutics. 
We could consistently show that DNA damage-
induced Chk1 activation was dependent on mTOR in 
all cell lines studied, suggesting that cells may rely on 
mTOR-Chk1 signalling for survival. Numerous studies 
have demonstrated that Chk1 inhibition following DNA 
damage potentiates DNA damage-induced cell death via 
multiple mechanisms [48-53]. Importantly, this study has 
revealed an unexpected benefit of mTORC1/2 inhibitors 
in their ability to inhibit Chk1 activity and cell cycle 
arrest. We show reduced cell survival when mTORC1/2 
is inhibited in the presence of genotoxic stress and report 
that mTORC2 is essential for Chk1 activation. Our data 
provides new mechanistic insight into the role of mTOR 
in the DNA damage response and support the clinical 
development of mTORC1/2 inhibitors in combination with 
DNA damage-based therapies for breast cancer. 
MATERIALS AND METHODS
Reagents
Etoposide, PP242 and rapamycin were purchased 
from Sigma Aldrich, Gillingham, UK. ATM specific 
inhibitor (# 118500), cycloheximide and MG-132 were all 
purchased from Merck Millipore, Watford, UK. 
Cell culture
All cell lines were grown at 37°C and 5% CO2 and 
maintained in Dulbecco’s modified Eagle medium (PAA 
Laboratories, Yeovil, UK) supplemented with 10% fetal 
bovine serum (Sigma-Aldrich), 100 IU/mL penicillin, 
100 µg/mL streptomycin and 2 mM glutamine and 1% 
Fungizone amphotericin B (all purchased from Life 
Technologies, Paisley, UK). Matched human colorectal 
carcinoma cells (HCT116 p53+/+ and p53-/-) were kindly 
provided by Professor Galina Selivanova (Karolinska 
Institute, Stockholm, Sweden). HBL100 and MDA-
MB-231 cell lines were a gift from Dr Kay Colston (St 
George’s, University of London, UK). 
HEK293, MCF7 and HCC1937 cells were obtained 
from American Type Culture Collection (Manassas, VA, 
USA). 
UV-irradiation
Cells were seeded in 6 cm dishes and grown to 50-
70% confluence. Medium was removed, replaced with 
PBS and cells were exposed to ultraviolet radiation (UV) 
for various time points. PBS was aspirated and replaced 
with DMEM containing 10% FBS and left to recover for 
various times. Thereafter, whole-cell lysates were assayed 
by western blot as previously described [54].
Gene silencing with siRNAs
1.5×104/cm2 HEK293 cells were seeded for 2-4 
hrs until attached. Cells were transiently transfected 
with 25 nM of siRNA duplexes using HiPerfect reagent 
(QIAGEN, Crawley, UK,) according to the manufacturer’s 
instructions and as previously described [55]. mTOR 
siRNA (#6381) was purchased from Cell Signaling (New 
England Biolabs, Hitchin, UK), Raptor (sc-44069) and 
Rictor (sc-61478) siRNA duplexes were purchased from 
Santa Cruz (CA, USA). AllStars siRNA duplex (QIAGEN) 
was used as negative control. Following addition of siRNA 
duplexes, etoposide was added at 4, 16 or 48 hrs prior to 
the end of a total 72 hrs in siRNA and cells were harvested 
on ice for flow cytometry and western blot analysis. 
Real-time quantitative PCR 
Total RNA was extracted from cells using the 
RNeasy Mini Kit (QIAGEN) and 50 ng total RNA was 
used for first-strand cDNA synthesis using Sensiscript 
(QIAGEN) according to the manufacturer’s instructions. 
Real-time qPCR was performed with GoTaq qPCR master 
mix (Promega, Southampton, UK) in a Stratagene Mx3000 
real time cycler (Agilent Technologies, Stockport, UK). 
Primers for Chk1 were purchased from Sigma-Aldrich 
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(forward 5’-GGTGCCTATGGAGAAGTTCAA; reverse 
5’-TCTACGGCACGCTTCATATC) [56]. Primers for 
GAPDH have been described previously [55].
Western blotting 
Experiments with cell lines were carried out as 
indicated in the figure legends and cells were lysed 
in 2×Laemmli buffer and protein concentration was 
determined using the Lowry assay, as previously 
described [54]. Proteins were separated by SDS-PAGE 
and transferred on to PVDF to be probed with specific 
antibodies. Actin was purchased from Merck Millipore; 
all other antibodies were from Cell Signaling, NEB. 
Flow cytometry
Flow cytometry was performed as previously 
described [24]. Following treatment, cells were harvested 
on ice and fixed in 70% ethanol for at least 1 hr at -20°C. 
Thereafter, cells were washed in PBS and resuspended in 
50 µg/mL propidium iodide/RNAse A solution (0.5 mL 
per 106 cells) (Sigma-Aldrich) for 30 min in the dark at 
room temperature. The percentage of cells in different 
phases of cell cycle was analysed with a Beckman Coulter 
Cytomics FC500 flow cytometer.
MTT cell viability assay
Cells were seeded in 96-well plates and treated as 
indicated in the figure legends. Thereafter, 25 µl of MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium 
bromide) (Sigma-Aldrich) reagent was added to each 
well and incubated at 37°C for 2 hrs. Cells were lysed by 
addition of 100 µl of 10% SDS per well, and incubated 
at 37°C for 16 hrs before measurement of absorbance in 
a spectrophotometer (SpectraMax340PC384, Molecular 
Devices) at 595 nm.
Statistical analysis
Two-way ANOVA was performed with Bonferroni 
multiple comparisons post-test that allowed determination 
of statistical significance between multiple samples 
simultaneously. 
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